Prognostic Roles of Metabolic Reprogramming-associated Genes in Patients with Hepatocellular Carcinoma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 Nov 14

PMID 33188160

Citations 11

Authors

Lijuan Cui

Huan Xue

Zhitong Wen

Zhihong Lu

Yunfeng Liu

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming for adaptation to the tumor microenvironment is recognized as a hallmark of cancer. Although many altered metabolic genes have been reported to be associated with tumor pathological processes, systematic analysis of metabolic genes implicated in hepatocellular carcinoma prognosis remains rare. The aim of this study was to identify key metabolic genes related to hepatocellular carcinoma, and to explore their clinical significance. We downloaded mRNA expression profiles and clinical hepatocellular carcinoma data from The Cancer Genome Atlas database to explore the prognostic roles of metabolic genes. Five prognosis-associated metabolic genes, including and were screened via univariate Cox regression analysis and a LASSO Cox regression model, which divided patients into high- and low-risk groups. Furthermore, gene set enrichment analysis revealed that significantly-enriched gene ontology terms and pathways involving high-risk patients were focused on regulation of nucleic and fatty acid metabolism. Taken together, our study identified five metabolic genes related to survival, which can be used to predict the prognosis of patients with hepatocellular carcinoma. These genes may play essential roles in metabolic microenvironment regulation, and represent potentially important candidate targets in metabolic therapy.

Citing Articles

Signature of immune-related metabolic genes predicts the prognosis of hepatocellular carcinoma.

Zhuo W, Xia H, Lan B, Chen Y, Wang X, Liu J Front Immunol. 2024; 15:1481331.

PMID: 39654885 PMC: 11625796. DOI: 10.3389/fimmu.2024.1481331.

Prognostic model development and clinical correlation of eight key genes in skin cutaneous melanoma.

Ma C, Xie L Heliyon. 2024; 10(13):e33930.

PMID: 39071565 PMC: 11283098. DOI: 10.1016/j.heliyon.2024.e33930.

Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis.

Liu L, Wang Q, Wu L, Zhang L, Huang Y, Yang H Cancer Cell Int. 2023; 23(1):138.

PMID: 37452331 PMC: 10349470. DOI: 10.1186/s12935-023-02949-z.

An Inflammation-Associated Prognosis Model for Hepatocellular Carcinoma Based on Adenylate Uridylate- (AU-) Rich Element Genes.

Song L, Su X, Lu Y, Hua D, Gao Z Mediators Inflamm. 2023; 2023:2613492.

PMID: 37181805 PMC: 10169245. DOI: 10.1155/2023/2613492.

Association of Mutations in Replicative DNA Polymerase Genes with Human Disease: Possible Application of Models for Studies.

Yamaguchi M, Cotterill S Int J Mol Sci. 2023; 24(9).

PMID: 37175782 PMC: 10178534. DOI: 10.3390/ijms24098078.

References

Sinkala M, Mulder N, Martin D . Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers. Commun Biol. 2019; 2:414. PMC: 6856368. DOI: 10.1038/s42003-019-0666-1. View

Sun L, Suo C, Li S, Zhang H, Gao P . Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer. 2018; 1870(1):51-66. DOI: 10.1016/j.bbcan.2018.06.005. View

Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi P, Wang Y . Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep. 2018; 23(1):255-269.e4. PMC: 5916795. DOI: 10.1016/j.celrep.2018.03.077. View

Starokadomskyy P, Gemelli T, Rios J, Xing C, Wang R, Li H . DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol. 2016; 17(5):495-504. PMC: 4836962. DOI: 10.1038/ni.3409. View

Zuo S, Wei M, Zhang H, Chen A, Wu J, Wei J . A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer. J Transl Med. 2019; 17(1):152. PMC: 6515678. DOI: 10.1186/s12967-019-1899-y. View

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

Porta C, Sica A, Riboldi E . Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. FEBS J. 2017; 285(4):717-733. DOI: 10.1111/febs.14288. View

Lyssiotis C, Kimmelman A . Metabolic Interactions in the Tumor Microenvironment. Trends Cell Biol. 2017; 27(11):863-875. PMC: 5814137. DOI: 10.1016/j.tcb.2017.06.003. View

Tarasenko T, McGuire P . The liver is a metabolic and immunologic organ: A reconsideration of metabolic decompensation due to infection in inborn errors of metabolism (IEM). Mol Genet Metab. 2017; 121(4):283-288. PMC: 5553615. DOI: 10.1016/j.ymgme.2017.06.010. View

10.

Wu S, Zheng J, Li Y, Yu H, Shi S, Xie W . A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. Clin Cancer Res. 2017; 23(22):6904-6911. DOI: 10.1158/1078-0432.CCR-17-1510. View

11.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

12.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Yu S, Li X, Guo X, Zhang H, Qin R, Wang M . UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma. IUBMB Life. 2018; 71(1):105-112. DOI: 10.1002/iub.1941. View

15.

Chiu D, Tse A, Xu I, Cui J, Lai R, Li L . Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517. PMC: 5593860. DOI: 10.1038/s41467-017-00530-7. View

16.

Mateo J, Harden T, Boyer J . Functional expression of a cDNA encoding a human ecto-ATPase. Br J Pharmacol. 1999; 128(2):396-402. PMC: 1571647. DOI: 10.1038/sj.bjp.0702805. View

17.

Li X, Huang L, Leng X . Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation. J Cancer Res Clin Oncol. 2018; 144(12):2465-2474. PMC: 6244647. DOI: 10.1007/s00432-018-2756-8. View

18.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

19.

Kuo F, Mar B, Lindsley R, Lindeman N . The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017; 130(4):433-439. PMC: 5813726. DOI: 10.1182/blood-2017-03-734533. View

20.

Hofmann E, Boyanapalli M, Lindner D, Weihua X, Hassel B, Jagus R . Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol. 1998; 18(11):6493-504. PMC: 109235. DOI: 10.1128/MCB.18.11.6493. View